Cite
Chounta V, Overton ET, Mills A, et al. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M). Patient. 2021;14(6):849-862doi: 10.1007/s40271-021-00524-0.
Chounta, V., Overton, E. T., Mills, A., Swindells, S., Benn, P. D., Vanveggel, S., van Solingen-Ristea, R., Wang, Y., Hudson, K. J., Shaefer, M. S., Margolis, D. A., Smith, K. Y., & Spreen, W. R. (2021). Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M). The patient, 14(6), 849-862. https://doi.org/10.1007/s40271-021-00524-0
Chounta, Vasiliki, et al. "Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)." The patient vol. 14,6 (2021): 849-862. doi: https://doi.org/10.1007/s40271-021-00524-0
Chounta V, Overton ET, Mills A, Swindells S, Benn PD, Vanveggel S, van Solingen-Ristea R, Wang Y, Hudson KJ, Shaefer MS, Margolis DA, Smith KY, Spreen WR. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M). Patient. 2021 Nov;14(6):849-862. doi: 10.1007/s40271-021-00524-0. Epub 2021 May 31. PMID: 34056699; PMCID: PMC8563641.
Copy
Download .nbib